Vertex Pharmaceuticals Inc.
NASDAQ · VRTX·Boston, MA·Pharma·Approved
Dominant CF franchise holder (Trikafta/Kaftrio) expanding into pain (suzetrigine/Journavx), gene editing (Casgevy with CRISPR Therapeutics for SCD/beta-thal), and kidney disease. Vertex's pipeline leverages its small-molecule and cell/gene therapy capabilities across serious diseases.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Vertex Q1 2026 Earnings Presentation | Earnings | May 4, 2026 | 19 |